Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivonescimab - Akeso Biopharma

Next Previous
Drug Profile

Ivonescimab - Akeso Biopharma

Alternative Names: AK-112; PD-1/VEGF bi-specific antibody - Akeso Biopharma; SMT-112

Latest Information Update: 19 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akeso Biopharma
  • Developer Akeso Biopharma; Summit Therapeutics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Non-small cell lung cancer
  • Phase II Colorectal cancer; Gynaecological cancer; Triple negative breast cancer
  • Phase I/II Ovarian cancer; Solid tumours
  • Phase I Small cell lung cancer

Most Recent Events

  • 13 Mar 2024 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (IV)
  • 13 Mar 2024 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Italy (IV) (NCT05184712)
  • 20 Feb 2024 Akeso Biopharma and Summit Therapeutics has 14 patents pending for Ivonescimab
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top